Myovant Sciences (MYOV) Rose 55% Over The Year, Recently Found Pfizer As A Major Partner

In the United States and Canada, pharmaceutical corporation Myovant Sciences Inc. (MYOV) has recently signed a collaboration deal with Pfizer Inc. (PFE) to create and support relugolix.

Created by Myovant Sciences, the drug relugolix is targeted at treating some female disorders as well as male prostate cancer. As part of the cooperation, it is understood that Myovant Sciences will obtain an advance payment of $650 million from Pfizer. Based on the accomplishment of benchmarks, the corporation still has the right to another $200 million. Based on meeting those net revenue milestones of relugolix, Myovant Sciences will also earn tiered sales stage payouts. Furthermore, the profits from the selling of the drug would similarly be split by both companies.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Pfizer also has exclusive rights in the United States and Canada to market relugolix (except some Asian countries). Myovant Sciences will earn another $50 million and double-digit royalties on sales of the drug if Pfizer takes advantage of this chance.

The contract is important for Myovant Sciences, as Pfizer has more financial and human capital in multiple markets to sell the drug. This year, in collaboration with Pfizer, Myovant Sciences will start selling relugolix as a cure for advanced prostate cancer.

Relugolix’s promise is not yet completely realized because it is not been approved yet. But by June 1, 2021, the FDA plans to take a vote on the approval of a combined medication with relugolix for the treatment of uterine fibroids. In the first half of the year, Myovant Sciences already plans to apply for approval of its medication for the treatment of endometriosis.

Myovant Sciences Inc. (MYOV) stock was stable on Thursday with a slight rise of 0.23% o close the session at $21.46. Over the week, the stock is at a loss of 14.77% which increases t more than 22% since the year’s start. However, in over the year trading, the stock is at an increase of nearly 55% raising its market capitalization to just over $2 billion.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.